

RECEIVED

CENTRAL FAX CENTER

MAR 09 2004

OFFICIAL

FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICEApplicants Docket Number:
USST98017 US PCTApplicants:
PARKER, et alSerial No.
09/719,758Filing Date:
January 4, 2002Title of Invention:
MONOCLONAL ANTIBODIES DIRECTED AGAINST THE G3BP PROTEIN AND USES

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, L. R. Helms, at (571)273-0832, on

Date of Deposit March 4, 2004

Printed Name of Person Signing Certificate Jonas Pierre, Sr.

Signature _____

Total Number of Pages Sent: 18

Attorney: Joel B. German

Reg. No. 48,676

Group Art Unit: 1642

Examiner: L. R. Helms

TO: Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input checked="" type="checkbox"/> Copy of Amendment filed on December 16, 2003 | <input type="checkbox"/> Fee Transmittal |
| <input checked="" type="checkbox"/> Copy of Statement In Support of Biological Deposit filed on December 16, 2003 | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Copy of Statement in Support of Filing and Submission of Sequence Listing filed on December 16, 2003 | <input checked="" type="checkbox"/> Other <u>Return Postcard stamped received by the USPTO</u> |
| <input checked="" type="checkbox"/> Copy of Sequence Listing filed on December 16, 2003 | <input checked="" type="checkbox"/> Other <u>Response to Examiner's Request</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Receipt Confirmed:

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKER, et al.

Examiner: L. R. Helms

Art Unit: 1642

Application No.: 09/719,758

Filed: January 4, 2002

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to Examiner L. R. Helms at
571-273-0862, Alexandria, VA 22313, on

March 4, 2003

Date of Transmission

Jonas Pierre
Signature

RESPONSE TO EXAMINER'S REQUEST

Mail Stop PCT
Attn: Examiner L. R. Helms
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Dear Examiner Helms,

Per your request, enclosed with this letter you will find documents the Applicants filed with their response of December 16, 2003 to the Office Action dated July 17, 2003.

1. Amendment
2. Statement in Support of Biological Deposit
3. Statement in Support of Filing and Submission of Sequence Listing
4. Sequence Listing

Also enclosed is a copy of the return postcard stamped received by the USPTO on December 18, 2003 confirming the above documents were timely filed.

Respectfully submitted,


Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. USST98017 US PCT

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKER ET AL.

Examiner: L. R. Helms

Art Unit: 1642

Serial No.: 09/719,758

Filed: January 4, 2002

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
care of Art Unit 1642, at 703-305-3014 on

Date of Deposit

09/05/2002 Proctor 10/16/03

Printed Name of Person Signing Certificate

[Signature]

Statement in Support of Biological Deposit

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Roxane Demoncour, declare as follows:

1. I am patent senior manager at Aventis Pharma S.A.
2. The above-referenced application refers to a deposit on June 9, 1998, under the number I-2038 at the Collection Nationale de Cultures de Micro-organismes of antibodies designated Mab 1F1 and secreted by the hybridoma line G3B 1F1 1D1.
3. During pendency of the application, access to the deposit will be afforded the Commissioner upon request.
4. All restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application.
5. The deposits will be maintained in a public depository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest.

6. The deposits will be replaced if they should become nonviable or non-replicable.

7. I declare under the laws of the United States of America that all statements of fact set forth above are true, and recognize that willfully false statements may jeopardize the validity of any patent that issues from this application.

Date:

Dec. 15, 2003

Roxane Denoncourt

Name

PAGE 36/36 * RCVD AT 3/4/2004 4:29:39 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730862 * CSID:908 231 2626 * DURATION (mm:ss):07:46